ArticlePDF AvailableLiterature Review

Abstract

Objective: The aim of this review was to summarize the literature regarding the impact of the menopause transition on body weight and body composition. Methods: We conducted a search of the literature using Medline (Ovid, 1946-present) and PubMed (1966-2012) for English-language studies that included the following search terms: 'menopause', 'midlife', 'hormone therapy' or 'estrogen' combined with 'obesity', 'body weight' or 'body composition'. Results: Whereas weight gain per se cannot be attributed to the menopause transition, the change in the hormonal milieu at menopause is associated with an increase in total body fat and an increase in abdominal fat. Weight excess at midlife is not only associated with a heightened risk of cardiovascular and metabolic disease, but also impacts adversely on health-related quality of life and sexual function. Animal and human studies indicate that this tendency towards central abdominal fat accumulation is ameliorated by estrogen therapy. Studies mostly indicate a reduction in overall fat mass with estrogen and estrogen-progestin therapy, improved insulin sensitivity and a lower rate of development of type 2 diabetes. Conclusion: The hormonal changes across the perimenopause substantially contribute to increased abdominal obesity which leads to additional physical and psychological morbidity. There is strong evidence that estrogen therapy may partly prevent this menopause-related change in body composition and the associated metabolic sequelae. However, further studies are required to identify the women most likely to gain metabolic benefit from menopausal hormone therapy in order to develop evidence-based clinical recommendations.
CLIMACTERIC 2012;15:419–429
REVIEW Received 12-06-2012
© 2012 International Menopause Society Revised 23-06 -2012
DOI: 10.3109/13697137.2012.707385 Accepted 25-06 -2012
Correspondence: Professor S. R. Davis, Women s Health Research Program, Department of Epidemiology and Preventive Medicine, Monash University,
Melbourne 3004, Austr alia
Understanding weight gain at menopause
S. R. Davis , C. Castelo-Branco
*
, P. Chedraui
, M. A. Lumsden
, R. E. Nappi
*
*
, D. Shah
and P. Villaseca
as the Writing Group of the International Menopause Society for World Menopause Day 2012
Women s Health Research Program, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne,
Australia;
*
Unit of Endocrinological Gynaecology, Department of Gynaecology, ICGON, Hospital Clínic de Barcelona, Universitat
de Barcelona, IDIBAPS, Barcelona, Spain;
Institute of Biomedicine, Facultad de Ciencias M é dicas, Universidad Cat ó lica de
Santiago de Guayaquil, Guayaquil, Ecuador;
Head of Reproductive & Maternal Medicine, School of Medicine, University of
Glasgow, Scotland, UK;
*
*
Research Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, IRCCS S.
Matteo Foundation, University of Pavia, Italy;
Department of Obstetrics and Gynecology, Breach Candy Hospital and Research
Center, Jaslok Hospital and Research Center, Sir Hurkisondas Hospital and Research Center, Mumbai, India;
Department of
Endocrinology, Faculty of Medicine, Pontifi cia Universidad Cat ó lica de Chile, Santiago, Chile
Key words: MENOPAUSE , OBESITY , WEIGHT GAIN , ESTROGEN
ABSTRACT
Objective The aim of this review was to summarize the literature regarding the impact of the menopause
transition on body weight and body composition.
Methods We conducted a search of the literature using Medline (Ovid, 1946 present) and PubMed
(1966 2012) for English-language studies that included the following search terms: menopause , midlife ,
hormone therapy or estrogen combined with obesity , body weight or body composition .
Results Whereas weight gain per se cannot be attributed to the menopause transition, the change in the
hormonal milieu at menopause is associated with an increase in total body fat and an increase in abdominal
fat. Weight excess at midlife is not only associated with a heightened risk of cardiovascular and metabolic
disease, but also impacts adversely on health-related quality of life and sexual function. Animal and human
studies indicate that this tendency towards central abdominal fat accumulation is ameliorated by estrogen
therapy. Studies mostly indicate a reduction in overall fat mass with estrogen and estrogen progestin therapy,
improved insulin sensitivity and a lower rate of development of type 2 diabetes.
Conclusion The hormonal changes across the perimenopause substantially contribute to increased abdomi-
nal obesity which leads to additional physical and psychological morbidity. There is strong evidence that
estrogen therapy may partly prevent this menopause-related change in body composition and the associated
metabolic sequelae. However, further studies are required to identify the women most likely to gain metabolic
benefi t from menopausal hormone therapy in order to develop evidence-based clinical recommendations.
INTRODUCTION
For women aged 55 65 years, weight gain is one of their
major health concerns
1 . This is understandable as obesity is
one of the most common nutrition-related disorders globally,
and its prevalence is increasing. World-wide, the prevalence
of obesity has more than doubled since 1980. In 2008, 1.5
billion adults, 20 years and older, were overweight (body
mass index (BMI) 25 29.9 kg/m
2 ), including both developed
and developing countries. Of these, over 200 million men and
nearly 300 million women were obese (BMI
30 kg/m
2 )
2 .
Moreover, the rates of obesity have increased notably in
developing countries adopting a Western lifestyle (decreased
physical activity and overconsumption of cheap, energy-dense
food). The sharp increase in overweight and obesity rates
observed in the last 20 years is dependent on, or controlled
by, several factors and is only in part attributable to changes
in lifestyle.
The deleterious effects of obesity are diverse, ranging from
an increased risk of premature death to several non-fatal dis-
eases with an adverse impact on quality of life. Obesity is a
major risk factor for diabetes mellitus and the cardiovascular
diseases, coronary heart disease, infarction, stroke, and hyper-
tension
2 . However, the relationship between obesity and meta-
bolic disease is complex. There is increasing recognition of a
metabolically healthy but obese phenotype, observed in about
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
420
9% of obese men and 16% of obese women
3 . The lower rate
of cardiometabolic abnormalities in metabolically healthy
obese individuals is not explained by diet composition or level
of physical activity, highlighting the importance of a genetic
contribution to the predisposition to the co-morbidities of
obesity
4 . Obesity is also a major risk factor for urinary incon-
tinence, dementia, some cancers (endometrial, breast and
colon) and musculoskeletal disorders, especially osteoarthritis,
a highly disabling degenerative disease of the joints
2 .
Obesity has substantial psychosocial consequences. Depres-
sion and depressive symptoms are common among obese
patients. As increasingly evidenced in the literature, obesity
substantially affects health-related quality of life (HRQOL)
5 7 .
It affects physical competence, appearance, self-esteem and
social functioning. There are no clear differences between
gender and ethnicity in these outcomes.
In general, obesity is characteristically more prevalent in
females than in males. Several explanations have been pro-
posed to explain this sex difference in obesity; however, none
have been conclusive. Fluctuations in sex hormones at differ-
ent stages of reproductive life, such as menarche, pregnancy,
and menopause transition, may play a role in the adipose tis-
sue expansion.
The menopause transition begins with the onset of men-
strual irregularities and ends with the last menstrual period.
Numerous studies have demonstrated that the menopausal
transition is associated with unfavorable changes in body
composition, abdominal fat deposition and general health
outcomes; for this reason, it is mandatory to investigate the
changes in these risk factors during the menopausal transition.
This review summarizes and discusses the contribution of the
menopause transition to obesity in women.
METHODS
The literature was searched using Medline (Ovid, 1946 present)
and PubMed (1966 2012) for English-language studies that
included the following search terms: menopause , midlife ,
hormone therapy or estrogen combined with obesity ,
body weight or body composition .
IS WEIGHT GAIN AT MIDLIFE A CONSEQUENCE
OF MENOPAUSE OR AGING?
The studies that have focussed on the question of whether
midlife weight gain is simply a function of age or due to the
hormonal changes that occur in relation to menopause have
concluded that the steady weight gain of about 0.5 kg annu-
ally is due to age rather than the menopause itself
8 10 . These
include both cross-sectional comparisons of weight in women
of similar chronological age but varying menopausal status
(premenopause, perimenopause and postmenopause) and lon-
gitudinal studies that have examined the rate of weight change
and the impact of menopausal status and hormonal change.
In addition, consideration of both ethnicity and physical
activity is important since these have a profound effect on
both obesity and fat distribution
11 13 .
The Study of Women s Health Across the Nation (SWAN)
included fi ve ethnic groups in the US: Caucasians, African-
Americans, Hispanic, Chinese and Japanese
14 . In a telephone
survey of 16 000 study participants, no difference in self-
reported BMI was found between premenopausal and post-
menopausal women, adjusting for age and other covariants
15 .
This result was confi rmed in a small cross-sectional study of
energy expenditure, body composition and menopausal status
conducted as part of the SWAN, which also considered impact
of ethnicity. This sub-study reported that the median weight
of the Chinese pre- and early postmenopausal women was not
statistically different from that of the late perimenopausal and
postmenopausal women
16 . The median weight of the white
women in the study was signifi cantly greater than that of the
Chinese, and it also did not differ by menopausal status.
The mean weight gain over 3 years in the SWAN cohort as a
whole was 2.1 kg, but was unrelated to menopausal status
8 .
In summary, weight gain does not appear to be affected by
the hormonal changes of the menopause.
EFFECTS OF LOSS OF OVARIAN HORMONE
PRODUCTION ON WEIGHT AND
BODY COMPOSITION
Findings from animal models
Studies in animal models indicate that changes in the hor-
monal milieu at menopause contribute to changes in body
composition and fat distribution. Studies in mice have dem-
onstrated that the loss of ovarian function promotes a diet-
independent increase in adipose tissue mass and associated
metabolic pathologies
9 . Several studies have shown that
oophorectomy results in obesity in mice
17,18 . Oophorecto-
mized mice exhibit decreased energy expenditure, without
concomitant change in energy intake, resulting in adipocyte
hypertrophy, adipose tissue infl ammation and the develop-
ment of fatty liver
17 . However, when supplemented with
17 β -estradiol, oophorectomized mice are protected from
developing hepatic steatosis and insulin resistance
18 . In this
model, estradiol supplementation also protected against
adipocyte hypertrophy and adipose tissue oxidative stress and
infl ammation
18 . That central fat accumulation is a conse-
quence of estrogen defi ciency is also supported by studies of
aromatase gene knock-out (ArKO) mice, which cannot
synthesize endogenous estrogens. Female ArKO mice exhibit
obesity by as early as 3 months of age, which is characterized
by marked increases in the gonadal and infra-renal fat pads
19 .
This increased adiposity is not simply due to hyperphagia or
reduced resting energy expenditure but, as in oophorecto-
mized mice, is associated with reduced energy expenditure
due to reduced physical activity
20 . Studies of female mice with
total body deletion of the estrogen receptor- α (ER α ) (ER α -
knock-out mice), have reported similar fi ndings
21 . Estradiol
replacement in female ArKO mice primarily results in reduced
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
Climacteric 421
adipocyte volume with little change in factors that control
de novo adipocyte fatty acid synthesis, suggesting that changes
in the uptake of lipids from the circulation are the main mech-
anisms by which estradiol regulates fat accumulation
19 .
In addition to estrogen defi ciency being associated with
reduced energy expenditure, there is also evidence from ani-
mal models that estrogen is important for feeding behaviors
and meal size
21 . Estrogen may have direct actions through
ER α or act indirectly to decrease orexigenic peptides and
decrease food intake, as reviewed in detail by Brown and
Clegg
21 .
Taken together, the available data from animal models
indicate that estrogen depletion favors central abdominal fat
accumulation, and studies in animals indicate that this is
ameliorated by estrogen therapy.
Findings from human studies
The prevalence of abdominal obesity is almost double that of
general obesity, with rates in the US in 2008 of 65.5% in
women aged 40 59 years and 73.8% in women aged 60 years
or more
22 . It has been suggested that BMI but not menopausal
status determines central adiposity in postmenopausal women.
However, there is substantial evidence that the perimenopause
is associated with a more rapid increase in fat mass and redis-
tribution of fat to the abdomen, resulting in a transition from
a gynoid to an android pattern of fat distribution and an
increase in total body fat
11 . Studies using a range of radiologi-
cal modalities have shown that postmenopausal women have
greater amounts of intra-abdominal fat compared to pre-
menopausal women
23,24 . Waist circumference represents both
subcutaneous and visceral adipose tissue depot size and cor-
relates closely with cardiovascular disease risk. In women, it
is also closely associated with dyslipidemia
25 . The waist-to-
hip ratio is another indicator of accumulation of visceral fat
which can also be quantitated by CT scanning
26 .
Abdominal fat can be considered an endocrine organ due
to its capacity to secrete adipokines and other substances that
are closely associated with metabolic diseases such as insulin
resistance, type 2 diabetes and the metabolic syndrome
27 .
Aging and the menopause transition are each associated with
changes in adipose tissue metabolism, which may contribute
to the accumulation of body fat after menopause
28 .
Deleterious changes in infl ammatory markers and adipo-
kines correlate strongly with increased visceral adiposity at
menopause
29 . The transport protein, serum sex hormone
binding globulin (SHBG), is a strong independent marker of
insulin resistance
30 32 and type 2 diabetes risk
33 and has been
increasingly implicated in the pathogenesis of type 2 diabetes
and cardiovascular disease
33 35 . SHBG levels in postmeno-
pausal women are negatively correlated with visceral fat
26,36
and an adverse adipokine profi le
37 . Importantly, the relation-
ship between SHBG and insulin resistance in postmenopausal
women is independent of both endogenous estrogens and
androgens
38 . Thus, a high waist circumference, indicating
accumulation of excessive central abdominal fat, and a low
SHBG level are independent predictors of metabolic disease
risk in postmenopausal women.
A signifi cant change in waist circumference in relation to
nal menstrual period has been observed
39 and signifi cant
increases in central abdominal fat have been reported from
longitudinal studies of Caucasian and Asian women
40,41 .
Signifi cant increases in total fat mass, percentage fat mass,
truncal fat mass and visceral fat have been seen in non-obese
premenopausal women followed over several years
40 . The
women who became perimenopausal or postmenopausal by
the third follow-up year showed a signifi cant increase in
visceral fat ( p 0.01) compared with baseline. Weight circum-
ference and fat mass (measured by bio-electrical impedance)
have also been observed to increase in relation to the fi nal
menstrual period
42 . These changes occurred similarly in both
African-American and Caucasian women.
Within Asia, different ethnic groups exhibit different levels
of insulin resistance, and ethnicity modifi es the relationship
between insulin resistance and type 2 diabetes that is related
to an increase in central adiposity
43,44 and possibly decreased
activity
43 . Women of Indian origin have a signifi cantly ele-
vated risk of type 2 diabetes but the impact of menopause
itself on this risk is unclear. Studies of the menopause transi-
tion and changes in body composition in Chinese women
suggest that the menopause has an independent effect on
the increase in fat mass as well as an increase in central
adiposity
41 .
Consistent with weight gain primarily being infl uenced by
age, not menopause, the published literature does not support
an adverse effect of spontaneous premature ovarian failure
(POF) on body weight and, in general, women with POF tend
to be leaner
45 . However, data pertaining to fat distribution in
women with spontaneous POF are lacking. Central obesity is
common in women with premature ovarian failure due to
Turner syndrome. The distinct anthropometrical composition
of women with Turner syndrome is associated with higher
BMI and waist-to-hip ratio, as well as increased fat mass,
central adiposity and liver adiposity when compared with age-
matched normal controls
46 . Even so, Turner syndrome patients
show a different metabolic pattern than that seen in natural
menopause: they frequently have abnormal glucose tolerance
and high triglycerides, but with decreased insulin secretion
instead of the expected hyperinsulinemia. It is speculated that
these women may have impaired pancreas β -cell function,
hypothetically due to the involvement of still unknown
X-chromosome genes
47 .
OTHER FACTORS INFLUENCING WEIGHT
GAIN IN MIDLIFE
Obesity is substantially infl uenced by genetic, demographic, social
and behavioral factors. Globally, obesity in women is inversely
associated with poorer education and urbanization
48,49 . Other
factors that have been found to signifi cantly predict obesity
in women include a low level of activity, parity, family his-
tory of obesity and marriage at earlier age
48 . Although
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
422
traditionally obesity has been related to food intake and activ-
ity, there is increasing evidence that disruption of circadian
rhythms and timing of food intake, as seen with shift work,
and sleep deprivation may contribute to weight gain
50 .
Although it seems intuitive that factors such as skipping
breakfast, daily eating frequency, snacking, irregular meals,
eating away from home, consumption of fast food, take-away
food intake, consumption of large food portions and eating
until full might predict obesity, the literature in this area
remains inconclusive due to methodological discrepancies
between studies
51,52 .
Obesity is associated with psychological distress and low
self-esteem and there is evidence for obesity predicting devel-
opment of depression. However, intrapersonal and contex-
tual factors may confound the relationship between obesity
and depression due to the variable perception of body image
issues by women according to culture. Furthermore, a spec-
trum of depression can be increased food intake and
decreased physical activity
53 and women who experience
depression tend to gain more weight across adulthood
54 .
Most population-based studies report an association between
obesity and depression
55 and a bidirectional relationship has
been found in women between depression and type 2 diabe-
tes
56 . The perimenopause is associated with a higher vulner-
ability to depression, with the risk increasing from early to
late perimenopause and decreasing during postmenopause
57 .
Weight gain and increased BMI have been related to anxiety
and depression and low life satisfaction during the meno-
pause transition
58,59 .
Diverse psychotropic drugs are also associated with
weight gain, with negative metabolic consequences. Second-
generation antidepressants are the mainstay of management
of major depression. These include selective serotonin
reuptake inhibitors (SSRIs), serotonin and norepinephrine
reuptake inhibitors (SNRIs), and other drugs with related
mechanisms of action that selectively target neurotransmit-
ters. Some SSRIs and SNRIs are more associated with weight
gain than others. Other commonly used psychotropics
associated with weight gain include clozapine, imipramine,
and amitriptyline
60 . These drugs have been found to up-
regulate sterol regulatory element-binding proteins, which are
involved in cellular cholesterol and fatty acid biosynthesis
71 .
In contrast, the antidepressants which in general are not
associated with weight gain, ziprasidone and buproprion,
have little effect on these proteins
60 .
Many studies have provided evidence that weight gain is
common during chemotherapy. There is consistency in the
observation of a signifi cant change in body composition with
an increase in total body fat and in abdominal and visceral
adiposity, while lean mass stays unchanged or slightly
decreases
61 . These changes are not attributable to a change in
resting energy expenditure
61 . Decreased voluntary energy
expenditure, not increased food intake, appears to contribute
to the observed weight gain
61 . Women who experience ovar-
ian failure during treatment have signifi cantly more weight
gain than those who remain premenopausal
62 , with greater
gains observed in truncal fat
63 .
DOES OBESITY OR WEIGHT GAIN ALTER
THE MENOPAUSE TRANSITION?
When analyzing weight increase during the menopausal tran-
sition, there are two important considerations: fi rst, the effect
of body weight over the course of the transition, including its
effect on age at natural menopause (ANM), and, second, its
effect on menopausal symptoms.
Excessive body weight and age at
natural menopause
It is well established that obesity may be associated with
altered menstrual cycle length and hormone patterns in
premenopausal women, with longer cycles due to increase in
length of the follicular phase. The rate of premenopausal BMI
increase and premenopausal episodic weight loss of more than
5 kg have been independently associated with a later ANM
64 .
A later ANM has also been associated with being a non-
smoker, higher adult weight, higher BMI, greater alcohol
consumption, regular strenuous exercise and not being
vegetarian
65 . In contrast, premenopausal smoking and type
2 diabetes predict an earlier ANM.
Longitudinal studies indicate that the greater the BMI, the
later the ANM
66 . In the Penn Ovarian Aging Study, there was
a positive association between BMI and the odds of transi-
tioning from pre- to perimenopause but not from peri- to
postmenopause
67 .
The ANM is determined by genetic factors. There are
several possible pathways and genomic regions which have
been associated with ANM. Nevertheless, fi ndings to date are
not conclusive. That obesity is in part genetically determined
is known. Enzymes involved in steroid production such as
aromatase and type 1 17 β -hydroxysteroid dehydrogenase
(HSD) can exert infl uence over estradiol levels during the
menopausal transition, particularly in obese women. The
decline in estradiol is more rapid in non-obese women
68 . For
obese women, selected variations in the aromatase gene and
type 1 17 β -HSD gene result in different estradiol trajectories
around the fi nal menstrual period and, hence, different
postmenopausal estradiol levels
68 . Thus, genetic factors may
link both ANM and BMI.
In conclusion, there is a potential circular relationship
between adiposity and the menopause. It seems that there is
a substantial effect of obesity and adiposity on the magnitude
of the hormonal changes experienced during the transition.
Nevertheless, there are other factors aside from BMI infl uencing
the ANM which may be more relevant such as genetic
predisposition, intrauterine development and subclinical
ovarian pathology.
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
Climacteric 423
Effect of increased weight during the menopausal
transition over menopausal symptoms
The prevalence and severity of menopausal symptoms depend
on several factors. These include not only the hormonal
changes imposed by the transition, but also psychosocial fac-
tors. During the menopausal transition, as weight increases
so do menopausal symptoms. Obesity is an independent risk
factor for more severe menopausal symptoms
69 71 .
Obesity and menopausal bone loss
Obese women appear to lose bone at a lower rate than non-
obese women across the menopause transition
72 . However,
the relationship between osteoporosis, fracture risk and
excessive BMI is complex. Low BMI has been associated
with osteoporosis and women with long-standing obesity
have been observed to be less at risk for osteoporosis and
fracture
73 . These views have recently been challenged by the
results provided by the Global Longitudinal study of
Osteoporosis in Women
74 . This study included 60 393
women
55 years from ten countries and assessed patient
characteristics, fracture history, fracture risk factors, and
anti-osteoporosis medications. Using fracture as the endpoint,
the risk of incident ankle and upper leg fractures was
signifi cantly higher in obese women, while the risk of wrist
fracture was signifi cantly lower. Obese women with fracture
were more likely to have experienced early menopause and
to report two or more falls in the past year. In this population,
self-reported co-morbid conditions were highly prevalent,
including asthma, emphysema, and type 1 diabetes, and
more common in obese women with incident fracture. These
data clearly suggest that obesity is not protective against
fracture in postmenopausal women
74 .
Impact of weight gain on psychosexual well-being
at menopause
Apart from being at increased risk for a variety of chronic
diseases, overweight women may suffer from psychosocial
consequences, with a signifi cant impact on self-esteem and
general well-being
75 .
A review of eight studies examining HRQOL among women
aged over 55 years old concluded that obese postmenopausal
women have lower HRQOL in physical functioning, energy,
and vitality compared with normal-weight women
76 . Given
the evidence that mood disorders are one of the most impor-
tant co-morbid conditions of sexual dysfunction in postmeno-
pausal women, it is plausible that weight gain and obesity at
menopause may be risk factors for poor sexual functioning.
However, little is known of the specifi c impact of weight gain
on sexual function at menopause as a consequence of the
domino effect of other menopausal symptoms, especially
psychological symptoms. Indeed, loss of fi tness and weight
gain were not the sole factors infl uencing the intensity of
sexual complaints in a clinical sample of menopausal women
77 .
In peri- and postmenopausal women with urinary inconti-
nence, increased BMI early in menopause represents a risk not
only for urinary incontinence, but also for sexual dysfunction.
Arousal, orgasm, lubrication and satisfaction are inversely
correlated with BMI
78 .
Amongst obese postmenopausal women, the percentage of
women with sexual problems is greatest in those with
abdominal obesity
79 . Sexual well-being is adversely affected
by insulin-resistance and the metabolic syndrome
80 , and
sexual dysfunction is more prevalent in postmenopausal
women with metabolic syndrome in comparison with healthy
controls
81 . The third Princeton Consensus Conference reported
that women with the metabolic syndrome/obesity have more
sexual dysfunction than those without, and treatment of the
metabolic syndrome/obesity improves sexual function
82 .
Although cardiometabolic risk factors, diabetes, and coronary
heart disease are associated with more sexual dysfunction in
women, there are no data showing that sexual dysfunction is
a predictor of future cardiovascular events in women, as is
evident in men
82 .
That notwithstanding, there is a need for more research
into the association between female sexual health and vascular
risk factors.
Weight loss and menopausal symptom
improvement
Reductions in weight, BMI and abdominal circumference have
been associated with a reduction in vasomotor symptoms in
overweight and obese women
83 . The combination of dietary
modifi cation and exercise also has positive effects on HRQOL
and psychological health, which may be greater than that
from exercise or diet alone
84 . Improvements in weight, aerobic
tness and psychosocial factors may mediate some of the
effects of these interventions on HRQOL
84 . Weight loss in
overweight and obese women improves psychological well-
being, HRQOL, self-esteem and health practices
85,86 . In
addition, dietary weight loss and exercise exert a positive
effect over insulin resistance in postmenopausal women,
which together with a decrease in menopausal symptoms may
potentially decrease cardiovascular risk.
DOES MENOPAUSAL HORMONE THERAPY
AFFECT WEIGHT AND BODY COMPOSITION?
A Cochrane Review published in 2000 reported no evidence
of an adverse effect of estrogen-only or estrogen progestin
therapy on body weight or BMI
87 . There has been no subse-
quent research that would challenge this conclusion.
The effects of estrogen therapy in postmenopausal women
on body composition vary, with most randomized, controlled
trials showing a reduction in central adiposity
88 91 and a few
not
92 . In a subsample of women participating in the Women s
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
424
Health Initiative estrogen plus progestin (EPT) study, who had
body composition measurements at baseline and year 3, the
EPT intervention at 3 years signifi cantly helped to maintain
lean body mass and prevented a shift toward android fat dis-
tribution
90 . However, the size of the effect was small.
Although, overall, the effects of exogenous estrogen appear
to be favorable in terms of body composition, the route of
estrogen delivery may have subtle, but differing effects
93,94 .
Oral estrogen has been associated with a small but signifi cant
increase in fat mass and a decrease in lean mass, whereas lean
body mass and fat mass do not change signifi cantly with
transdermal estradiol
93,94 . Neither route appears to alter vis-
ceral fat mass
93 . The differing effect of oral versus transdermal
estrogen therapy may relate to the differing effects of oral
versus transdermal estrogen on growth factors and substrate
oxidation. Oral estrogen, but not transdermal estrogen, is
associated with a signifi cant decline in circulating insulin-like
growth factor 1 (IGF-1)
95 98 . This appears to be due to oral
estrogen impairing hepatic IGF-I production, which then
causes increased secretion of growth hormone through reduced
feedback inhibition
99 . Divergent effects on fat mass have also
been seen for oral raloxifene and transdermal estradiol. In
growth hormone-replaced hypopituitary women, treatment
with transdermal estradiol was associated with a reduction in
fat mass. This effect was attenuated when the women were
treated with raloxifene
100 .
Despite the divergent effects of oral and transdermal estro-
gen noted above, improved insulin sensitivity has been
observed with oral EPT
92 , and both oral estrogen-alone and
EPT may reduce the incidence of type 2 diabetes
101 .
In summary, menopausal hormone therapy is not associated
with increased weight or increased visceral adiposity. Studies
mostly indicate a reduction in overall fat mass with estrogen
and estrogen progestin therapy, improved insulin sensitivity
and a lower rate of development of type 2 diabetes.
STRATEGIES TO PREVENT/MANAGE
WEIGHT GAIN
Management strategies for weight reduction in obese
individuals include physical activity, calorie-controlled diet,
pharmacotherapy or bariatric surgery. Complementary and
alternative treatments such as acupuncture, yoga, and herbal
supplements may also aid in weight loss. These strategies may
be used alone or in combination for greater effi cacy.
Physical activity
Physical activity has an inverse relationship with weight and
waist circumference independent of aging and change in
menopausal status
11 . Hence, active midlife women have an
advantage as they approach menopause with a lower BMI,
lower fat mass, greater lean mass and less central obesity. Even
though physical activity may not entirely prevent weight gain
with age, it may protect against the development of obesity
14 .
Sixty minutes/day of moderate-intensity activity are essential
to maintain normal weight
102 . One unit increase in physical
activity score decreases 4 cm
2 of intra-abdominal fat
12 . There
is concern about loss of muscle and bone mass with weight
loss in older women. Resistance exercise has been shown to
preserve lean mass during weight loss
103 .
Calorie-controlled diet
Calorie restriction alone can elicit reduction in body weight,
total body and visceral fat, similarly to exercise. The addition
of exercise, with a weight loss of more than 5%, can reduce
risk factors for cardiovascular disease, such as dyslipidemia,
hypertension, and diabetes mellitus
104 .
Conventional diets are defi ned as those providing calories
below energy requirements but above 800 kcal/day
105 . Options
include balanced low-calorie diets, low-fat low-calorie diets,
moderate-fat low-calorie diets, low-carbohydrate diets, and
the Mediterranean diet. An important determinant of weight
loss is adherence to the diet, irrespective of the particular
macronutrient composition. A diet based upon patient prefer-
ences may improve long-term adherence.
Ideally, any calorie-restricted diet should result in the lowest
possible loss of protein, keeping the calories from fat to below
30% of total calorie intake. If a low-carbohydrate diet is chosen,
healthy choices for fat (mono- and polyunsaturated) and protein
(fi sh, nuts, legumes, and poultry) should be encouraged. If a
low-fat diet is chosen, increases in healthy carbohydrates (fi sh,
vegetables, whole grains) should be selected. It has been sug-
gested that low carbohydrates may be more effective for weight
loss than low-fat diets. However, weight losses at 6 months and
at 2 years have been found to be similar for diets with differing
carbohydrate and fat macronutrient contents
106 .
Pharmacotherapy
Anti-obesity medications are pharmacological agents that
reduce or control weight. These drugs act by suppressing
appetite and increasing satiety, increasing the metabolism of
the body and interfering with the body s ability to absorb
specifi c nutrients in food
107 .
Orlistat, sibutramine and rimonabant have been studied in
trials of 1 year and longer. Attrition rates averaged 30 40%,
limiting the validity of studies. All three anti-obesity agents
signifi cantly achieved 5 10% weight loss and had differing
effects on cardiovascular risk and adverse effect profi les.
At present, only one anti-obesity medication, orlistat (gas-
trointestinal lipase inhibitor) is currently approved for long-
term use. Sibutramine and rimonabant have been withdrawn
due to side-effects, including myocardial infarction, stroke
and serious psychiatric disorders, respectively
108 . Herbal
products have been used as supplements to aid weight loss
but have not been found to be signifi cantly effective
109 . Weight
loss with pharmacological intervention is not sustained when
therapy is discontinued.
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
Climacteric 425
Metformin, a drug approved for treatment of diabetes mel-
litus
110 , has been known to produce weight loss of 1 2 kg
over a 12-month period. Although metformin does not pro-
duce enough weight loss (5%) to qualify as a weight-loss
drug , it is a useful choice for overweight individuals who
have diabetes or are at high risk for diabetes
111 .
Bariatric surgery
Bariatric surgery is a clinical and cost-effective intervention
for moderate to severely obese people compared to other
non-surgical interventions. The different surgical procedures
include gastric bypass, vertical banded gastroplasty, adjust-
able gastric banding, and laparoscopic sleeve gastrectomy.
In a systematic review of the effect of surgical versus non-
surgical options, a statistically signifi cant difference was seen
in fi ve out of six randomized, controlled trials. In two cohort
studies that reported the outcome at the end of 2 years,
signifi cant weight loss, varying between 16 and 28.6%, was
demonstrated as compared to the non-surgical group in
which there was weight gain. On comparison of different
surgical procedures, gastric bypass was found to be more
effective than vertical banded gastroplasty. No statistically
signifi cant difference was found in the amount of weight
loss and quality of life between open versus laparoscopic
surgery
112 .
Traditional health practices and medicines
Several studies of yoga among the middle-aged and elderly
have shown improved metabolic parameters
113 . Long-term
Hatha yoga practice is linearly associated with a decrease in
BMI
114 . An intensive yoga intervention helped to decrease
waist circumference and improve quality of life in overweight
and obese breast cancer survivors
115 . Yoga improves adi-
ponectin levels, serum lipids, and metabolic syndrome risk
factors in obese postmenopausal women. Consequently,
regular yoga practice may be effective in preventing cardio-
vascular disease caused by obesity
116 .
The effectiveness and safety of traditional Chinese
medicine, including Chinese herbal medicine (CHM) and
acupuncture, provide an alternative established therapy.
Acupuncture is believed to induce weight loss via its
regulatory effects on nerve and endocrine functions. Laser
acupuncture has been found to exert a therapeutic effect on
BMI and weight
117 .
A review of 96 randomized, controlled trials comprising
49 trials of CHM, 44 trials of acupuncture and three trials
of combined therapy has found that CHM and acupuncture
were more effective than placebo or lifestyle modifi cation
in reducing body weight. CHM and acupuncture were
found to have a similar effi cacy as anti-obesity drugs but
with fewer reported adverse effects. However, these conclu-
sions were limited by small sample size and low quality of
methodologies
118 .
In summary, various modalities are available for weight
loss in obesity. Lifestyle changes such as healthy diet, physical
activity and yoga are recommended for long-term results.
Bariatric surgery is accepted as an obesity surgery, with excel-
lent results related to weight loss and reduction in morbidity
due to metabolic syndrome. The use of acupuncture and
CHM merits further investigation. No effective and safe drug
is yet available for weight loss.
CONCLUSIONS
Obesity is a public health problem, with overweight individu-
als representing approximately 20% of the adult world popu-
lation
119 . Consistent fi ndings are that age, not menopause, is
the main determinant of weight gain at midlife, but that the
hormonal changes across the perimenopause substantially
contribute to increased central abdominal fat and abdominal
obesity. Abdominal obesity is not only associated with
increased cardiovascular and metabolic disease risk, and can-
cer, but also sexual dysfunction and poorer health-related
quality of life.
Weight control has an essential role in postmenopause
health and should be considered early in the perimenopause
to safeguard the quality of life of women. Weight loss
through diet and increased physical activity has been shown
to alleviate menopausal symptoms. Contrary to widespread
belief, menopausal hormone therapy is not associated with
weight gain and may ameliorate perimenopausal accumula-
tion of abdominal fat. Hormone therapy has also been asso-
ciated with lower rates of type 2 diabetes. In addition to
reducing food intake and increasing activity, interventions
including acupuncture and Chinese herbal medicine may be
benefi cial for weight loss. However, like dietary and activity
modifi cation, these approaches also require individual com-
mitment. As central weight gain with menopause is associ-
ated with the development of insulin resistance, there is
increasing interest in the use of metformin to ameliorate this
metabolic change and thus prevent or delay progression to
type 2 diabetes.
In summary, weight gain with age is a global sociodemo-
graphic issue that is not a consequence of the menopause. In
contrast, increased central abdominal fat appears to be a
direct consequence of the menopause. It may be prevented by
estrogen therapy and possibly by the use of metformin.
KEY POINTS
Weight gain is a major health concern for women at
midlife.
Weight gain per se does not appear to be affected by the
hormonal changes of the menopause.
The fall in estrogen at menopause favors central abdomi-
nal fat accumulation.
Other factors that may contribute to obesity in women
include a low level of activity, parity, lower level of
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
426
education, a family history of obesity, use of psychotropic
drugs and chemotherapy.
In addition to the adverse physical consequences of obesity,
weight excess is a major risk factor for psychological dis-
tress, low self-esteem, depression and sexual dysfunction.
Obesity is an independent risk factor for more severe
menopausal symptoms.
Estrogen-only or estrogen progestin therapy does not
adversely affect body weight and may ameliorate accu-
mulation of abdominal fat.
Methods of weight loss must include increased exercise
and calorifi c control although this can be enhanced by
surgery, drug therapy and non-medical means.
Metformin is a useful drug for selected overweight indi-
viduals who have diabetes or are at high risk for diabetes.
Successful maintenance of weight loss involves lifestyle
change.
Confl ict of interest During the past 2 years, Professor S.
R. Davis has had a fi nancial relationship (member of advisory
boards and/or consultant or investigator) with Bayer-Schering
Pharma, Warner Chilcott, Biosante and Trimel Pharmaceuti-
cals; Professor R. E. Nappi has had a fi nancial relationship
(lecturer, member of advisory boards and/or consultant) with
Bayer-Schering Pharma, Eli Lilly, Merck Sharpe & Dohme,
Novo Nordisk, Pfi zer Inc; Professor P. Villaseca has had a
nancial relationship (member of advisory board) with Glaxo-
SmithKlein; Professor C. Castelo-Branco has had a fi nancial
relationship (lecturer and/or consultant or investigator) with
Pierre Fabre Labs, Merck Spain, Amgen and Isdin; Dr D. Shah
has had a fi nancial relationship (member of advisory board)
with Elder Pharmaceuticals, India. Professor M. A. Lumsden
is currently an advisor to Abbott Pharmaceuticals.
Source of funding Nil.
References
Nappi RE , Kokot-Kierepa M . Vaginal Health: Insights, Views & 1.
Attitudes (VIVA) results from an international survey . Climac-
teric 2012 ; 15 : 36 44
World Health Organization . Obesity and overweight. Fact sheet 2.
N ° 311, May 2012 . Available from: http://www.who.int/media-
centre/factsheets/fs311/en/
Pajunen P , Kotronen A , Korpi-Hyovalti E , 3. et al . Metabolically
healthy and unhealthy obesity phenotypes in the general popula-
tion: the FIN-D2D Survey . BMC Public Health 2011 ; 11 : 754
Hankinson AL , Daviglus ML , Van Horn L , 4. et al . Diet composi-
tion and activity level of at risk and metabolically healthy obese
American adults . Obesity 2012 Apr 19. Epub ahead of print
Wee C , Davis R , Hamel M . Comparing the SF-12 and SF-36 5.
health status questionnaires in patients with and without obe-
sity . Health Qual Life Outcomes 2008 ; 6 : 11 15
Wadden TA , Phelan S . Assessment of quality of life in obese 6.
individuals . Obes Res 2002 ; 10(Suppl 1) : 50-7S
Fjeldstad C , Fjeldstad AS , Acree LS , Nickel KJ , Gardner AW . 7.
The infl uence of obesity on falls and quality of life . Dyn Med
2008 ; 7 : 4
Sternfeld B , Wang H , Quesenberry OP , 8. et al . Physical activ-
ity and changes in weight and waist circumference in midlife
women: fi ndings from the Study of Women s Health across the
Nation
. Am J Epidemiol 2004 ; 160 : 912 22
Guthrie JR , Dennerstein L , Dudley EC . Weight gain and the 9.
menopause: a 5-year prospective study . Climacteric 1999 ; 2 :
205 11
Wing PR , Matthews KA , Kuller LH , 10. et al . Weight gain at the
time of the menopause . Arch Intern Med 1991 ; 15 : 97 102
Poehlman E , Toth MJ , Gardner A . Changes in energy balance 11.
and body composition at menopause: a controlled longitudinal
study . Ann Intern Med 1995 ; 123 : 673 8
Dugan SA , Everson-Rose SA , Karavolos K , 12. et al . Physical activ-
ity and reduced intra-abdominal fat in midlife African-American
and white women . Obesity 2010 ; 18 : 1260 5
Brown WJ , Williams L , Ford JH , Ball K , Dobson AJ . Identifying 13.
the energy gap: magnitude and determinants of 5-year weight
gain in midage women . Obes Res 2005 ; 13 : 1431 41
Sutton-Tyrrell K , Zhao X , Santoro N , 14. et al . Reproductive hor-
mones and obesity: 9 years of observation from the Study of
Women s Health Across the Nation (SWAN) . Am J Epidemiol
2010 ; 171 : 1203 13
Matthews KA
, Abrams B , Crawford S , 15. et al . Body mass index
in midlife women: relative infl uence of menopause, hormone use,
and ethnicity . Int J Obes Relat Metab Disord 2001 ; 25 : 863 73
Sternfeld B , Bhat AK , Wang H , 16. et al . Menopause, physical activ-
ity and body composition/fat distribution in midlife women .
Med Sci Sports Exerc 2005 ; 37 : 1195 202
Rogers NH , Perfi eld JW 2nd, Strissel KJ , Obin MS , Greenberg 17.
AS . Reduced energy expenditure and increased infl ammation
are early events in the development of ovariectomy-induced
obesity . Endocrinology 2009 ; 150 : 2161 8
Stubbins RE , Najjar K , Holcomb VB , Hong J , Nunez NP .18.
Oestrogen alters adipocyte biology and protects female mice
from adipocyte infl ammation and insulin resistance . Diabetes
Obes Metab 2012 ; 14 : 58 66
Misso M , Murata Y , Boon W , Jones M , Britt K , Simpson E . 19.
Cellular and molecular characterization of the adipose pheno-
type of the aromatase-defi cient mouse . Endocrinology 2003 ;
144 : 1474 80
Jones ME , Thorburn AW , Britt KL , 20. et al . Aromatase-defi cient
(ArKO) mice accumulate excess adipose tissue
. J Steroid
Biochem Molec Biol 2001 ; 79 : 3 9
Brown LM , Clegg DJ . Central effects of estradiol in the regula-21.
tion of food intake, body weight, and adiposity . J Steroid
Biochem Molec Biol 2010 ; 122 : 65 73
Flegal KM , Carroll MD , Ogden CL , Curtin LR . Prevalence 22.
and trends in obesity among US adults, 1999 2008 . JAMA
2010 ; 303 : 235 41
Toth MJ , T chernof A , Sites CK , Poehlman ET . Effect of meno-23.
pausal status on body composition and abdominal fat distribu-
tion . Int J Obes Relat Metab Disord 2000 ; 24 : 226 31
Toth MJ , Tchernof A , Sites CK , Poehlman ET . Menopause-24.
related changes in body fat distribution . Ann N Y Acad Sci
2000 ; 904 : 502 6
Wietlisbach V , Marques-Vidal P , Kuulasmaa K , Karvanen J , 25.
Paccaud F . The relation of body mass index and abdominal
adiposity with dyslipidemia in 27 general populations of the
WHO MONICA Project . Nutr Metab Cardiovasc Dis 2011
Dec 30. Epub ahead of print
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
Climacteric 427
Janssen I , Powell LH , Kazlauskaite R , Dugan SA . Testosterone 26.
and visceral fat in midlife women: the Study of Women’s Health
Across the Nation (SWAN) fat patterning study . Obesity
2010 ; 18 : 604 10
Wajchenberg BL . Subcutaneous and visceral adipose tissue: 27.
their relation to the metabolic syndrome . Endocr Rev 2000 ;
21 : 697 738
Misso ML , Jang C , Adams J , 28. et al . Differential expression of
factors involved in fat metabolism with age and the menopause
transition . Maturitas 2005 ; 51 : 299 306
Lee CG , Carr MC , Murdoch SJ , 29. et al . Adipokines, infl amma-
tion, and visceral adiposity across the menopausal transition: a
prospective study . J Clin Endocrinol Metab 2009 ; 94 : 1104 10
Jayagopal V , Kilpatrick ES , Jennings PE , Holding S , Hepburn 30.
DA , Atkin SL . The biological variation of sex hormone-binding
globulin in type 2 diabetes: implications for sex hormone-
binding globulin as a surrogate marker of insulin resistance .
Diabetes Care 2004 ; 27 : 278 80
Thadhani R , Wolf M , Hsu-Blatman K , Sandler L , Nathan D , 31.
Ecker JL . First-trimester sex hormone binding globulin and sub-
sequent gestational diabetes mellitus . Am J Obstet Gynecol
2003 ; 189 : 171 6
Goodman-Gruen D , Barrett-Connor E . Sex hormone-binding 32.
globulin and glucose tolerance in postmenopausal women. The
Rancho Bernardo Study . Diabetes Care 1997 ; 20 : 645 9
Perry JR , Weedon MN , Langenberg C , 33. et al . Genetic evidence
that raised sex hormone binding globulin (SHBG) levels reduce
the risk of type 2 diabetes . Hum Mol Genet 2009 ; 19 : 535 44
Ding EL , Song Y , Manson JE , 34. et al . Sex hormone-binding glob-
ulin and risk of type 2 diabetes in women and men . N Engl J
Med 2009 ; 361 : 1152 63
Peter A , Kantartzis K , Machann J , 35. et al . Relationships of circu-
lating sex hormone-binding globulin with metabolic traits in
humans . Diabetes 2010 ; 59 : 3167 73
Jorde R , Waterloo K , Storhaug H , Nyrnes A , Sundsfjord J , 36.
Jenssen TG . Neuropsychological function and symptoms in sub-
jects with subclinical hypothyroidism and the effect of thyroxine
treatment . J Clin Endocrinol Metab 2006 ; 91 : 145 53
Wildman RP , Wang D , Fernandez I , 37. et al . Associations of tes-
tosterone and sex hormone binding globulin with adipose tissue
hormones in midlife women . Obesity 2012 Apr 30. Epub ahead
of print
Davis SR , Robinson PJ , Moufarege A , Bell RJ . The contribution 38.
of SHBG to the variation in HOMA-IR is not dependent on
endogenous oestrogen or androgen levels in postmenopausal
women . Clin Endocrinol 2011 Nov 22. Epub ahead of print
Janssen I , Powell LH , Crawford S , Lasley B , Sutton-Tyrrell K . 39.
Menopause and the metabolic syndrome: the Study of Women’s
Health Across the Nation . Arch Intern Med 2008 ; 168 : 1568 75
Abdulnour J , Doucet E , Brochu M , 40. et al . The effect of the
menopausal transition on body composition and cardiometa-
bolic risk factors: a Montreal-Ottawa New Emerging Team
group study . Menopause 2012 ; 19 : 760 7
Ho SC , Wu S , Chan SG , Sham A . Menopausal transition and 41.
changes of body composition: a prospective study in Chinese
perimenopausal women . Int J Obes 2010 ; 34 : 1265 74
Sowers M , Zheng H , Tomey K , 42. et al . Changes in body compo-
sition in women over 6 years at midlife: ovarian and chrono-
logical aging . J Clin Endocrinol Metab 2007 ; 92 : 895 901
Khoo CM , Sairazi , Tasum N , 43. et al . Ethnicity modifi es the rela-
tionships of insulin resistance, infl ammation and adiponectin
with obesity in a multiethnic Asian population . Diabetes Care
2011 ; 34 : 1120 6
Gill J , Bhopal R , Douglas A , et al . Sitting time and waist cir-44.
cumference are associated with glycemia in UK South Asians:
data from 1228 adults screened for the PODOSA trial . Diabetes
Care 2011 ; 34 : 1214 18
Michalakis K ,
Coppack SW . Primary ovarian insuffi ciency: rela-45.
tion to changes in body composition and adiposity . Maturitas
2012 ; 71 : 320 5
Ostberg JE , Thomas EL , Hamilton G , Attar MJ , Bell JD , 46.
Conway GS . Excess visceral and hepatic adipose tissue in Turner
syndrome determined by magnetic resonance imaging: estrogen
defi ciency associated with hepatic adipose content . J Clin Endo-
crinol Metab 2005 ; 90 : 2631 5
Bakalov VK , Cooley MM , Quon MJ , 47. et al . Impaired insulin
secretion in the Turner metabolic syndrome . J Clin Endocrinol
Metab 2004 ; 89 : 3516 20
Hajian-Tilaki KO , Heidari
B . Prevalence of obesity, central 48.
obesity and the associated factors in urban population aged
20 70 years, in the north of Iran: a population-based study and
regression approach . Obes Rev 2007 ; 8 : 3 10
Huffman JE , Sabol C , Fried B . Infectivity, growth, survival, and 49.
pathogenicity of Zygocotyle lunata (Trematoda) in experimen-
tal rodent hosts . J Parasitol 1991 ; 77 : 280 4
Fonken LK , Workman JL , Walton JC , 50. et al . Light at night
increases body mass by shifting the time of food intake . Proc
Natl Acad Sci USA 2010 ; 107 : 18664 9
Bezerra IN , Curioni C , Sichieri R . Association between eating 51.
out of home and body weight . Nutr Rev 2012 ; 70 : 65 79
Mesas AE , Munoz-Pareja M , Lopez-Garcia E , Rodriguez-52.
Artalejo F . Selected eating behaviours and excess body weight:
a systematic review . Obes Rev 2012 ; 13 : 106 35
American Psychiatric Association . 53. Diagnostic and Statistical
Manual of Mental Disorders . Washington DC: American Psy-
chiatric Press , 1994
Sutin AR , Zonderman AB . Depressive symptoms are associated 54.
with weight gain among women . Psychol Med 2012 Apr 5.
Epub ahead of print
de Wit L , Luppino F , van Straten A , Penninx B , Zitman F , 55.
Cuijpers P . Depression and obesity: a meta-analysis of community-
based studies . Psychiatry Res 2010 ; 178 : 230 5
Pan A , Lucas M , Sun Q , 56. et al . Bidirectional association between
depression and type 2 diabetes mellitus in women . Arch Intern
Med 2010 ; 170 : 1884 91
Freeman EW . Associations of depression with the transition to 57.
menopause . Menopause 2010 ; 17 : 823 7
Llaneza P , Garc í a-Portilla MP , Llaneza-Su á rez D , Armott B , 58.
P é rez-L ó pez FR . Depressive disorders and the menopause tran-
sition . Maturitas 2012 ; 71 : 120 30
Fern á ndez-Alonso AM , Trabal ó n-Pastor M , Vara C , 59.
Chedraui P , P é rez-L ó pez FR; for The MenopAuse RIsk Assess-
ment (MARIA) Research Group . Life satisfaction, loneliness and
related factors during female midlife . Maturitas 2012 ; 72 : 88 92
Raeder MB , Ferno J , Vik-Mo AO , Steen VM . SREBP activation 60.
by antipsychotic- and antidepressant-drugs in cultured human
liver cells: relevance for metabolic side-effects? Mol Cell
Biochem 2006 ; 289 : 167 73
Demark-Wahnefried W , Peterson BL , 61. et al . Changes in weight,
body composition, and factors infl uencing energy balance
among premenopausal breast cancer patients receiving adju-
vant chemotherapy . J Clin Oncol 2001 ; 19 : 2381 9
Goodwin PJ , Ennis M , Pritchard KI , 62. et al . Adjuvant treatment
and onset of menopause predict weight gain after breast cancer
diagnosis . J Clin Oncol 1999 ; 17 : 120 9
Gordon AM , Hurwitz S , Shapiro CL , LeBoff MS . Premature 63.
ovarian failure and body composition changes with adjuvant
chemotherapy for breast cancer . Menopause 2011 ; 18 : 1244 8
Aydin ZD . Determinants of age at natural menopause in the 64.
Isparta Menopause and Health Study: premenopausal body
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
428
mass index gain rate and episodic weight loss . Menopause
2010 ; 17 : 494 505
Morris DH , Jones ME , Schoemaker MJ , McFadden E , 65.
Ashworth A , Swerdlow AJ . Body mass index, exercise, and
other lifestyle factors in relation to age at natural menopause:
analyses from the Breakthrough Generations Study . Am J
Epidemiol 2012 ; 175 : 998 1005
Akahoshi M , Soda M , Nakashima E , 66. et al . The effects of body
mass index on age at menopause . Int J Obes Relat Metab
Disord 2002 ; 26 : 961 8
Sammel MD , Freeman EW , Liu Z ,
Lin H , Guo W . Factors 67.
that infl uence entry into stages of the menopausal transition .
Menopause 2009 ; 16 : 1218 27
Sowers MR , Randolph JF , Zheng H , 68. et al . Genetic polymor-
phisms and obesity infl uence estradiol decline during the
menopause . Clin Endocrinol (Oxf) 2011 ; 74 : 618 23
Fern á ndez-Alonso AM , Cuadros JL , Chedraui P , Mendoza M , 69.
Cuadros AM , P é rez-L ó pez FR . Obesity is related to increased
menopausal symptoms among Spanish women . Menopause
Int 2010 ; 16 : 105 10
Chedraui P , Hidalgo L , Chavez D , Morocho N , Alvarado M , 70.
Huc A . Menopausal symptoms and associated risk factors
among postmenopausal women screened for the metabolic
syndrome . Arch Gynecol Obstet 2007 ; 275 : 161 8
Thurston RC , Sowers MR , Sternfeld B , 71. et al . Gains in body
fat and vasomotor symptom reporting over the menopausal
transition: the Study of Women’s Health across the Nation .
Am J Epidemiol 2009 ; 170 : 766 74
Sowers MR , Zheng H , Jannausch ML , 72. et al . Amount of bone
loss in relation to time around the fi nal menstrual period and
follicle-stimulating hormone staging of the transmenopause .
J Clin Endocrinol Metab 2010 ; 95 : 2155 62
van der Voort DJ , Geusens PP , Dinant GJ . Risk factors for 73.
osteoporosis related to their outcome: fractures . Osteoporos
Int 2001 ; 12 : 630 8
Compston JE , Watts NB , Chapurlat R , 74. et al . ; Glow Investiga-
tors . Obesity is not protective against fracture in postmenopau-
sal women: GLOW . Am J Med 2011 ; 124 : 1043 50
Shah MB . Obesity and sexuality in women . 75. Obstet Gynecol
Clin North Am 2009 ; 36 : 347 60 , ix
Jones GL , Sutton A . Quality of life in obese postmenopausal 76.
women . Menopause Int 2008 ; 14 : 26 32
Nappi RE , Verde JB , Polatti F , Genazzani AR , Zara C . 77.
Self-reported sexual symptoms in women attending menopause
clinics . Gynecol Obstet Invest 2002 ; 53 : 181 7
Pace G , Silvestri V , Guala L , Vicentini C . Body mass index, uri-78.
nary incontinence, and female sexual dysfunction: how they affect
female postmenopausal health . Menopause 2009 ; 16 : 1188 92
Llaneza P , I ñ arrea J , Gonzalez C , Alonso A , Arnott I , Ferrer- 79.
Barriendos J . Differences in health-related quality of life in a
sample of obese and non-obese menopausal Spanish women .
Maturitas 2007 ; 58 : 387 94
Llaneza P , Gonzalez C , Fernandez-Inarrea J , Alonso A , Arnott 80.
I , Ferrer-Barriendos J . Insulin resistance and health-related
quality of life in postmenopausal women . Fertil Steril 2009 ;
91 (Suppl) : 1370 3
Martelli V , Valisella S , Moscatiello S , 81. et al . Prevalence of sexual
dysfunction among postmenopausal women with and without
metabolic syndrome . J Sex Med 2012 ; 9 : 434 41
Miner M , Esposito K , Guay A , Montorsi P , Goldstein I . Cardio-82.
metabolic risk and female sexual health: the Princeton III
summary . J Sex Med 2012 ; 9 : 641 51
Huang AJ , Subak LL , Wing R , 83. et al . An intensive behavioral
weight loss intervention and hot fl ushes in women . Arch Intern
Med 2010 ; 170 : 1161 7
Imayama I , Alfano CM , Kong A , 84. et al . Dietary weight loss and
exercise interventions effects on quality of life in overweight/
obese postmenopausal women: a randomized controlled trial .
Int J Behav Nutr Phys Act 2011 ; 8 : 118
Rippe JM , Price JM , Hess SA , 85. et al . Improved psychological
well-being, quality of life, and health practices in moderately
overweight women participating in a 12-week structured weight
loss program . Obes Res 1998 ; 6 : 208 18
Garc í a Gonz á lez F , Ferrer Garc í a JC , Baixauli Rubio A , 86. et al .
[An ambulatory physical exercise program improves in the
short term weight and quality of life of obese post-menopausal
women] . Med Clin (Barc) 2009 ; 133 : 533 8
Norman RJ , Flight IH , Rees MC . Oestrogen and progesterone 87.
hormone replacement therapy for peri-menopausal and post-
menopausal women: weight and body fat distribution . Cochrane
Database Syst Rev 2000 ; (2) : CD001018
Yuksel H , Odabasi AR , Demircan S , 88. et al . Effects of oral con-
tinuous 17beta-estradiol plus norethisterone acetate replace-
ment therapy on abdominal subcutaneous fat, serum leptin
levels and body composition . Gynecol Endocrinol 2006 ; 22 :
381 7
Davis SR , Walker KZ , Strauss BJ . Effects of estradiol with and 89.
without testosterone on body composition and relationships
with lipids in post-menopausal women . Menopause 2000 ; 7 :
395 401
Chen Z , Bassford T , Green SB , 90. et al . Postmenopausal hormone
therapy and body composition a substudy of the estrogen plus
progestin trial of the Women’s Health Initiative . Am J Clin Nutr
2005 ; 82 : 651 6
Sorensen MB , Rosenfalck AM , Hojgaard L , Ottesen B . Obesity 91.
and sarcopenia after menopause are reversed by sex hormone
replacement therapy . Obes Res 2001 ; 9 : 622 6
Sites CK , L’Hommedieu GD , Toth MJ , Brochu M , Cooper BC , 92.
Fairhurst PA . The effect of hormone replacement therapy on
body composition, body fat distribution, and insulin sensitivity
in menopausal women: a randomized, double-blind, placebo-
controlled trial . J Clin Endocrinol Metab 2005 ; 90 : 2701 7
dos Reis CM , de Melo NR , Meirelles ES , Vezozzo DP , Halpern 93.
A . Body composition, visceral fat distribution and fat oxidation
in postmenopausal women using oral or transdermal oestrogen .
Maturitas 2003 ; 46 : 59 68
O’Sullivan AJ , Crampton LJ , Freund J , Ho KKY . The route of 94.
estrogen replacement therapy confer divergent effects on sub-
strate oxidation and body composition in postmenopausal
women . J Clin Invest 1998 ; 102 : 1035 40
Weissberger AJ , Ho KK , Lazarus L . Contrasting effects of oral 95.
and transdermal routes of estrogen replacement therapy on
24-hour growth hormone (GH) secretion, insulin-like growth
factor I, and GH-binding protein in postmenopausal women .
J Clin Endocrinol Metab 1991 ; 72 : 374 81
Sonnet E , Lacut K , Roudaut N , Mottier D , Kerlan V , Oger E . 96.
Effects of the route of oestrogen administration on IGF-1 and
IGFBP-3 in healthy postmenopausal women: results from a
randomized placebo-controlled study . Clin Endocrinol (Oxf)
2007 ; 66 : 626 31
Helle SI , Omsjo IH , Hughes SC , 97. et al . Effects of oral and
transdermal oestrogen replacement therapy on plasma levels of
insulin-like growth factors and IGF binding proteins 1 and 3: a
cross-over study . Clin Endocrinol (Oxf) 1996 ; 45 : 727 32
Cano A , Castelo-Branco C , Tarin JJ . Effect of menopause and 98.
different combined estradiol-progestin regimens on basal and
growth hormone-releasing hormone-stimulated serum growth
hormone, insulin-like growth factor-1, insulin-like growth fac-
tor binding protein (IGFBP)-1, and IGFBP-3 levels . Fertil Steril
1999 ; 71 : 261 7
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
Understanding weight gain at menopause Davis et al.
Climacteric 429
Kelly JJ , Rajkovic IA , O’Sullivan AJ , Sernia C , Ho KK . Effects 99.
of different oral oestrogen formulations on insulin-like growth
factor-I, growth hormone and growth hormone binding pro-
tein in post-menopausal women . Clin Endocrinol 1993 ; 39 :
561 7
Birzniece V , Meinhardt UJ , Gibney J , 100. et al . Differential effects
of raloxifene and estrogen on body composition in growth
hormone-replaced hypopituitary women . J Clin Endocrinol
Metab 2012 ; 97 : 1005 12
Bonds DE , Lasser N , Qi L , 101. et al . The effect of conjugated equine
oestrogen on diabetes incidence: the Women’s Health Initiative
randomised trial . Diabetologia 2006 ; 49 : 459 68
Institute of Medicine .
102. Dietary Reference Intake for Energy,
Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and
Amino Acids (macronutrients ) . Washington DC: National
Academies Press , 2002
Ross R , Dagnone D , Jones PJ , 103. et al . Reduction in obesity and
related comorbid conditions after diet-induced weight loss or
exercise-induced weight loss in men. A randomized, controlled
trial . Ann Intern Med 2000 ; 133 : 92 103
Douketis JD , Macie C , Thabane L , Williamson DF . Systematic 104.
review of long-term weight loss studies in obese adults: clinical
signifi cance and applicability to clinical practice . Int J Obes
2005 ; 29 : 1153 67
Freedman MR , King J , Kennedy E . Popular diets: a scientifi c 105.
review . Obes Rev 2001 ; 9(Suppl 1) : 1 40S
Sacks FM , Bray GA , Carey VJ , 106. et al . Comparison of weight-loss
diets with different compositions of fat, protein, and carbohy-
drates . N Engl J Med 2009 ; 360 : 859 73
National Institute for Health and Clinical Excellence . Clinical 107.
guideline CG43. Obesity: The prevention, identifi cation, assess-
ment and management of overweight and obesity in adults
and children. London, 2006 . http://guidance.nice.org.uk/CG43/
NICEGuidance/pdf/English
Ioannides-Demos LL , Piccenna L , McNeil JJ . Pharmacothera-108.
pies for obesity: past, current, and future therapies . J Obes
2011 ; 2011 : 179674
Chan CC , Koo MW , Ng EH , Tang OS , Yeung WS , Ho PC . 109.
Effects of Chinese green tea on weight, and hormonal and
biochemical profi les in obese patients with polycystic ovary syn-
drome a randomized placebo-controlled trial . J Soc Gynecol
Invest 2006 ; 13 : 63 8
Bray GA , Greenway FL . Current and potential drugs for treat-110.
ment of obesity . Endocr Rev 1999 ; 20 : 805 75
Knowler WC , Barrett-Connor E , Fowler SE , 111. et al . Reduction in
the incidence of type 2 diabetes with lifestyle intervention or
metformin . N Engl J Med 2002 ; 346 : 393 403
Picot J , Jones J , Colquitt JL , 112. et al . The clinical effectiveness and
cost effectiveness of bariatric surgery for obesity: a systematic
review and economic evaluation . Health Technol Assess 2009 ;
13 : 1
190 , 215 357, iii iv
Moliver N , Mika E , Chartrand M , Burrus S , Haussmann R , 113.
Khalsa S . Increased Hatha yoga experience predicts lower body
mass index and reduced medication use in women over 45 years .
Int J Yoga 2011 ; 4 : 77 86
Cohen BE , Chang AA , Grady D , Kanaya AM . Restorative yoga 114.
in adults with metabolic syndrome: a randomized, controlled
pilot trial . Metab Syndr Relat Disord 2008 ; 6 : 223 9
Littman AJ , Bertram LC , Ceballos R , 115. et al . Randomized con-
trolled pilot trial of yoga in overweight and obese breast cancer
survivors: effects on quality of life and anthropometric mea-
sures . Support Care Cancer 2012 ; 20 : 267 77
Lee JA , Kim JW , Kim DY . Effects of yoga exercise on serum 116.
adiponectin and metabolic syndrome factors in obese postmen-
opausal women . Menopause 2012 ; 19 : 296 301
Hu WL , Chang CH , Hung YC . Clinical observations on laser 117.
acupuncture in simple obesity therapy . Am J Chin Med 2010 ;
38 : 861 7
Sui Y , Zhao HL , Wong VC , 118. et al . A systematic review on use
of Chinese medicine and acupuncture for treatment of obesity .
Obes Rev 2012 ; 13 : 409 30
Lambrinoudaki I , Brincat M , Erel CT , 119. et al . EMAS Position
Statement: managing obese postmenopausal women . Maturitas
2010 ; 66 : 323 6
Climacteric Downloaded from informahealthcare.com by 81.36.62.83 on 02/26/15
For personal use only.
... The deficiency of estrogen occurring in menopause has a direct impact on metabolism and physiology, affecting lipid metabolism and energy consumption and fostering the storage of fat mass in abdominal/visceral parts of the body [77][78][79]. It has been well demonstrated that menopause is associated with weight gain. ...
... For instance, middle-aged women gained 0.7 kg per year in the SWAN study, whereas in the Nurse Health Study they gained an average of 3 kg over 8 years of follow-up, for an average of 0.4 kg [77,80]. Overall, the lean mass (muscles) decreases, whereas the fat mass increases [79]. As a result, menopause and perimenopause are associated with an increase in abdominal fat mass. ...
... As a result, menopause and perimenopause are associated with an increase in abdominal fat mass. In contrast, hormonal therapy (estrogen) could partially modulate the increase in abdominal fat and obesity [77,79]. Fat mass, in particular abdominal fat, could act as an endocrine organ and trigger the release of pro-inflammatory cytokines as well as fostering cardiometabolic comorbidities [77]. ...
Article
Full-text available
Women exhibit unique vulnerabilities in health, especially regarding mental health and neurodegenerative diseases. Biological, hormonal, and metabolic differences contribute to sex-specific risks that remain underrepresented in clinical studies. Diseases such as major depressive disorder (MDD) and Alzheimer’s disease (AD) are more prevalent in women and may be influenced by hormonal transitions, particularly during menopause. Chronic low-grade inflammation is emerging as a shared mechanism underlying both conditions, and this inflammatory state can be worsened by dietary habits. During menopause, mood and sleep disturbances can influence dietary behavior, leading to enhanced snacking and consumption of high-glycemic and comfort foods. Such foods, low in nutritional value, promote weight gain and elevated inflammatory markers. Their consumption combined (or not) with a preexisting Western diet pattern—already linked to inflammation—could reinforce systemic inflammation involving the gut–brain axis. Moreover, the symptoms “per se” could act on inflammation as well. Peripheral inflammation may cross the blood–brain barrier, sustaining mood disorders and promoting neurodegenerative changes. Finally, MDD and AD are both associated with conditions such as obesity and diabetes, which occur more frequently in women. The review highlights how menopause-related changes in mood, sleep, and diet may heighten susceptibility to mental and neurodegenerative diseases.
... In contrast, menopause, by itself, was not found to be independently associated with increases in blood pressure, insulin, or glucose levels beyond those attributed to aging [25,26], and changes in weight and body mass index observed over time in women do not appear to be related to menopause (both in premenopausal and postmenopausal women) [27]. That is, changes in weight were more strongly associated with chronological aging than with reproductive aging. ...
Article
Full-text available
Background and objective: Menopause is a significant physiological milestone in a woman’s life, coinciding with increased cardiovascular disease (CVD) risk due to various health-related changes. This narrative review focuses on cardiovascular health-related alterations during menopause and their implications on vascular function. Methods: An electronic database search was performed, drawing from sources such as PubMed and Google Scholar. Publications were included if they addressed CVD risk in peri- and postmenopausal women, and examined the impact of hormonal changes, traditional risk factors (e.g., hypertension, hyperlipidemia, diabetes), or lifestyle factors (e.g., diet, physical activity) on CVD. Results: Estrogen deficiency is pivotal, leading to adverse effects such as endothelial dysfunction, increased arterial stiffness, and lipid profile deterioration. Characteristics of menopause, including the age at onset, type or stage of menopause, and severity of symptoms, further modulate CVD risk. Additionally, the impact of traditional risk factors is amplified during this period. Strategies for the prevention of CVD in menopausal women are critically assessed, with a focus on lifestyle modifications, dietary interventions, and physical activity. Conclusions: This narrative review describes the potential benefits and risks of hormone therapy, alongside lipid-lowering therapies. Emphasis is placed on individualized risk assessment and management, highlighting the need for regular cardiovascular screenings and proactive management of risk factors.
... In addition to uterine health, significant reductions in perirenal and mesenteric fat weights were observed in both the Rex-and Rex-AG-treated groups, with Rex demonstrating a more pronounced effect ( Figure 5C,D). These results align with the well-documented pattern of adipose tissue redistribution during menopause, which often leads to increased central adiposity and heightened metabolic risks [40,41]. The reduction in adipose tissue weights suggests that Rex, and to a lesser extent Rex-AG, may help counteract postmenopausal metabolic shifts by modulating fat deposition patterns. . ...
Article
Full-text available
This study investigates the therapeutic potential of sophoricoside and its aglycone metabolite, genistein, derived from Styphnolobium japonicum L. fruit, as natural alternatives to hormone replacement therapy for postmenopausal symptom management. Using Lactobacillus plantarum to model intestinal biotransformation, we compared glycoside-rich (Rex) and aglycone-rich (Rex-AG) extracts in ovariectomized rats. Both treatments significantly reduced weight gain and alleviated vaginal dryness, with Rex demonstrating superior thermoregulatory stabilization. Histological and molecular analyses revealed preserved trabecular bone integrity through the downregulation of RANKL and upregulation of TGF-β. Both extracts exhibited potent anti-inflammatory effects in adipose tissue, suppressing IL-6 and TNF-α, while regulating adipogenesis markers (FABP4, KLF, leptin, PPARγ) more effectively than 17β-estradiol. Serum genistein concentrations confirmed its efficient biotransformation and systemic bioavailability. Importantly, the treatments showed favorable safety profiles with no adverse effects on organ weight. These findings establish S. japonicum L. fruit-derived phytoestrogens as promising candidates for the comprehensive management of postmenopausal symptoms, offering an efficacious and safer alternative to conventional hormone therapy.
... In bone health, the crucial loss of oestrogen results in an excessive production of the RANKL cytokine, promoting osteoclast genesis and enhanced bone resorption, a process associated with local inflammatory responses in the bone microenvironment [19]. Importantly, the hormonal shift after menopause causes weight gain that exerts substantial health consequences, which are closely linked to several well-established metabolic disturbances contributing to increased cardiovascular and metabolic risk [20][21][22]. Weight gain and related changes in visceral adipose tissue are associated with enhanced production and secretion of pro-inflammatory cytokines and adipokines. These have been attributed to an increased number of mature macrophages in the adipose tissue, causing chronic low-grade inflammation [23][24][25]. ...
... Alternatively, studies indicate that although estrogen depletion leads to an increase in total body fat, the concurrent decrease in lean body mass is thought to lead to little net change in total body weight (Kapoor, 2017;Leeners, 2017;Greendale, 2019). Notably, the prospective WHAM study by Price et al. found minimal differences in not only weight but also body composition of premenopausal patients two years after RRSO in comparison to patients who did not undergo RRSO, only noting an increase in abdominal visceral adipose tissue in the RRSO population (Price, 2023).Animal studies using models that mimic the postmenopausal hormonal milieu demonstrate a decrease in central abdominal fat accumulation as well as improved insulin sensitivity after exogenous estrogen therapy, indicating a role of hormonal regulation in postmenopausal weight gain (Davis, 2012). However, HRT in prospective studies such as WHAM does not appear to impact body composition significantly (Price, 2023). ...
Article
Full-text available
Introduction This study examines weight changes in premenopausal patients following risk-reducing salpingo-oophorectomy (RRSO) and factors associated with postoperative weight gain. Methods We analyzed data from premenopausal patients (age ≤ 51 years) with pathogenic variants in BRCA1/2, ATM, BRIP1, PALB2, RAD51C/D, MLH1, MSH2, MSH6, or PMS2 who underwent RRSO between 2009–2016. We defined postoperative weight gain as ≥ 5 % increase in weight within 5 years after RRSO and weight maintenance as < 5 % increase in weight or weight loss. Use of postoperative hormone replacement therapy (HRT) and referral to weight loss services were analyzed. Results 120 patients met inclusion criteria. Weight gain occurred in 44 (36.7 %) patients. There were no significant differences in demographic characteristics or comorbidities between groups. Preoperative weight and BMI were similar between cohorts. Mean postoperative weight and BMI were 82.4 ± 19.5 kg and 30.5 ± 6.9 kg/m², respectively, in the weight gain cohort compared to 73.1 ± 20.8 kg and 26.8 ± 7.3 kg/m² in the weight maintenance cohort (p = 0.017 and 0.008, respectively). 33 patients (27.5 %) received referrals to weight management services or underwent weight loss interventions. Referrals to weight management services were significantly higher in the weight gain cohort after RRSO (36.4 % vs. 19.7 %, p 0.045). Approximately 50 % of patients used HRT after surgery with similar rates of use in those who had weight gain (n = 42, 55.3 %) and weight maintenance (n = 19, 43.2 %; p = 0.20). Conclusions Over one third of patients experience weight gain after RRSO. Preoperative weight and BMI did not correlate with postoperative weight gain. These data highlight the need for targeted perioperative weight management in patients undergoing RRSO.
Article
Objectives: This study examines the association between obesity markers (body mass index, BMI and waist circumference, WC) and high-sensitivity C-reactive protein (hs-CRP) using data from 2,734 adult women aged 19 years or older from the Korea National Health and Nutrition Examination Survey (KNHANES). Methods: The mean hs-CRP levels in relation to BMI and WC was compared using analysis of covariance (ANCOVA), while sequentially adjusting for general characteristics (Model 1), health-related variables (Model 2), and clinical variables (Model 3). The statistical significance was set at p < 0.05. Results: Both BMI and WC were significantly associated with hs-CRP levels. However, WC was more strongly associated with elevated hs-CRP levels than was BMI as the degree of obesity increased. Participants with a WC of ≥ 100.0 cm presented higher hs-CRP levels (3.3 [0.3] mg/L) compared to those with a BMI of ≥ 30.0 kg/m² (2.1 [0.3] mg/L). Conclusions: While a WC ≥ 85.0 cm is currently used to define abdominal obesity, the marked increase in hs-CRP levels observed at WC ≥ 100.0 cm highlights the need for revised criteria for severe obesity. Incorporating inflammatory markers and WC into a multidimensional framework could improve the assessment of obesity-related risks.
Article
Research in preclinical models of menopause indicates that exogenously administered estrogens positively impact cognitive aging. However, clinical evidence indicates that the effects of estrogen therapy on cognition are inconsistent and may be modulated by pre-existing cardiometabolic conditions. The extent to which cardiometabolic health affects the cognitive outcomes of estrogen therapy remains unclear. This study aimed to determine whether variations in cardiometabolic health, both prior to and resulting from different estradiol treatment regimens, are related to the ability of estradiol to improve the cognitive aging trajectory in ovariectomized Long-Evans rats. Cognitive function and health status were assessed at 10 months of age after which rats were ovariectomized and administered vehicle or various estradiol treatments. Rats were assessed again at 18 (middle age) and 22 (old age) months. Cognition was evaluated using a spatial memory radial-maze task. Health status was determined through body composition analysis (dual-energy X-ray absorptiometry), glucose tolerance testing, and blood pressure and heart rate measurements (tail-cuff plethysmography). Results demonstrated that both continuous ongoing estradiol treatment and a previous 40-day estradiol exposure (terminated long before testing) significantly improved the cognitive aging trajectory from middle to old age. However, only continuous estradiol treatment had positive impacts on health measures; previous estradiol treatment provided no benefits to aging cardiometabolic systems. In contrast, a delayed estradiol treatment (initiated months after ovariectomy) provided no benefits for cognition but provided health benefits. Results indicated that estradiol impacts on cognition in healthy aging rats are separate from and not secondary to its effects on cardiometabolic health.
Article
Full-text available
Aim: Sedentary behavior and physical inactivity increase the risk of cardiometabolic diseases. It is important to evaluate physical activity in daily life and understand the influence of these factors on cardiometabolic diseases in the Japanese population, which tends to have a prolonged sitting time. We examined the association between sedentary behavior and physical inactivity, characterized by extended television (TV) viewing and low step counts, which are easily monitored and modifiable, and cardiometabolic risk factors in the Japanese population. Methods: This cross-sectional study included 2,531 Japanese adults (1,087 men and 1,444 women) 20–91 years old, randomly selected throughout Japan. TV viewing was assessed using a self-reported questionnaire, and step counts were measured using pedometers. Cardiometabolic risk factors were determined using physical examinations or blood samples. The association between sedentary behavior and physical inactivity with each risk factor was examined using a cross-sectional analysis with multivariate-adjusted logistic regression models. Results: In both sexes, longer TV viewing positively correlated with low high-density lipoprotein (HDL) cholesterol and high triglycerides (TG). In women, TV viewing time is associated with obesity and increased abdominal circumference (AC). Conversely, in men, lower step counts were positively associated with obesity and increased AC, low HDL cholesterol, and high TG levels. Conclusions: The association between prolonged TV viewing and cardiometabolic risk factors was more pronounced in women than in men, whereas the influence of lower step counts was stronger in men than in women. These findings contribute to the improvement of cardiovascular health by monitoring and managing individual screen times and step counts in daily life.
Article
Menopause marks a critical transition characterized by ceased ovarian function and declining estrogen levels, affecting multiple systems with vasomotor symptoms and genitourinary syndrome of menopause (GSM). Recent evidence shows vaginal microbiota undergoes significant alterations during menopause, influencing GSM severity. This comprehensive review examined vaginal microbiota dynamics in postmenopausal women through Predictive, Preventive, and Personalized Medicine (3PM/PPPM), revealing characteristic shifts—increased alpha diversity, reduced Lactobacillus dominance, and transitions toward non-Lactobacillus species—that serve as potential predictive biomarkers for the menopausal state, premature ovarian insufficiency, and GSM symptoms. The analysis evaluated microbiota-based risk stratification strategies for vaginal dysbiosis and demonstrated the effectiveness of both hormonal interventions (systemic/local estrogen, tibolone, ospemifene) and non-hormonal alternatives (probiotics, energy-based devices, pessary) in normalizing microbiota composition and improving vaginal health. The application of PPPM/3PM transformed menopausal healthcare from reactive to proactive precision-based care by establishing microbiota-based biomarkers that predict health risks, enable early targeted interventions tailored to specific microbiota profiles, and guide personalized treatment approaches based on individual microbial compositions. While this paradigm shift significantly advances gynecological medicine, research gaps remain in validating baseline microbiota signatures as predictive biomarkers and establishing standardized screening protocols. Further studies are needed to validate interventions such as probiotics and prebiotics, optimizing strain selection for personalized, evidence-based preventive and therapeutic strategies. Developing standardized yet personalized protocols to restore a balanced vaginal microbiome could help alleviate menopause-related symptoms. Advancing microbiota-based personalized therapeutic approaches is crucial to enhancing the quality of life for postmenopausal women through targeted and individualized vaginal health management.
Article
Background: It has been suggested that hormone therapy may help counter undesirable changes in body composition in older women. Objective: This study was designed to test whether estrogen plus progestin (E+P) therapy favorably affects age-related changes in body composition in postmenopausal women. Design: The substudy was composed of 835 women from the estrogen plus progestin trial of the Women’s Health Initiative who were randomly assigned to receive either E+P therapy (n = 437) or placebo (n = 398). The women had a mean age of 63.1 y and, on average, were 13.8 y past menopause. More than 17% of the participants were from an ethnic minority. No significant differences in baseline body composition (measured with dual-energy X-ray absorptiometry) by intervention assignment were observed. Results: After 3 y of intervention, the women who received active E+P therapy lost less lean soft tissue mass (−0.04 kg) than did the women who received placebo (−0.44 kg; P = 0.001). Additionally, the women in the E+P group had less upper-body fat distribution than did the women in the placebo group (change in ratio of trunk to leg fat mass: −0.025 for the E+P group and 0.004 for the placebo group; P = 0.003). A sensitivity analysis, which was conducted on the women who took ≥80% of the study medication during the intervention period, corroborated the findings from the intent-to-treat analysis. Conclusions: A 3-y E+P intervention significantly reduced both the loss of lean soft tissue mass and the ratio of trunk to leg fat mass in postmenopausal women. However, the effect sizes were small, and whether these changes in body composition lead to significant health benefits remains to be confirmed.
Article
I. Introduction II. Criteria for Evaluating the Efficacy of Antiobesity Treatment III. Physiological and Pharmacological Mechanisms to Reduce Food Intake A. Peripherally acting agents B. Centrally acting agents IV. Drugs That Alter Metabolism A. Preabsorptive agents B. Postabsorptive modifiers of nutrient metabolism V. Drugs That Increase Energy Expenditure A. Thyroid hormone B. Adrenergic thermogenic drugs VI. Conclusion
Article
OBJECTIVES To assess the clinical effectiveness and cost-effectiveness of bariatric surgery for obesity. DATA SOURCES Seventeen electronic databases were searched [MEDLINE; EMBASE; PreMedline In-Process & Other Non-Indexed Citations; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, DARE, NHS EED and HTA databases; Web of Knowledge Science Citation Index (SCI); Web of Knowledge ISI Proceedings; PsycInfo; CRD databases; BIOSIS; and databases listing ongoing clinical trials] from inception to August 2008. Bibliographies of related papers were assessed and experts were contacted to identify additional published and unpublished references. REVIEW METHODS Two reviewers independently screened titles and abstracts for eligibility. Inclusion criteria were applied to the full text using a standard form. Interventions investigated were open and laparoscopic bariatric surgical procedures in widespread current use compared with one another and with non-surgical interventions. Population comprised adult patients with body mass index (BMI) > or = 30 and young obese people. Main outcomes were at least one of the following after at least 12 months follow-up: measures of weight change; quality of life (QoL); perioperative and postoperative mortality and morbidity; change in obesity-related comorbidities; cost-effectiveness. Studies eligible for inclusion in the systematic review for comparisons of Surgery versus Surgery were RCTs. For comparisons of Surgery versus Non-surgical procedures eligible studies were RCTs, controlled clinical trials and prospective cohort studies (with a control cohort). Studies eligible for inclusion in the systematic review of cost-effectiveness were full cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost-consequence analyses. One reviewer performed data extraction, which was checked by two reviewers independently. Two reviewers independently applied quality assessment criteria and differences in opinion were resolved at each stage. Studies were synthesised through a narrative review with full tabulation of the results of all included studies. In the economic model the analysis was developed for three patient populations, those with BMI > or = 40; BMI > or = 30 and or = 30 and or = 30 and 40, ICERs were 18,930 pounds at two years and 1397 pounds at 20 years, and for BMI > or = 30 and < 35, ICERs were 60,754 pounds at two years and 12,763 pounds at 20 years. Deterministic and probabilistic sensitivity analyses produced ICERs which were generally within the range considered cost-effective, particularly at the long twenty year time horizons, although for the BMI 30-35 group some ICERs were above the acceptable range. CONCLUSIONS Bariatric surgery appears to be a clinically effective and cost-effective intervention for moderately to severely obese people compared with non-surgical interventions. Uncertainties remain and further research is required to provide detailed data on patient QoL; impact of surgeon experience on outcome; late complications leading to reoperation; duration of comorbidity remission; resource use. Good-quality RCTs will provide evidence on bariatric surgery for young people and for adults with class I or class II obesity. New research must report on the resolution and/or development of comorbidities such as Type 2 diabetes and hypertension so that the potential benefits of early intervention can be assessed.